Abstract The peroxisome proliferator-activated receptor gamma 1 (PPARc1) is a nuclear receptor that plays a pivotal role in breast cancer and is highly over-expressed relative to normal epithelia. We have previously reported that the expression of PPARc1 is mediated by at least six distinct promoters and expression in breast cancer is driven by a tumor-specific promoter (pA1). Deletional analysis of this promoter fragment revealed that the GC-rich, 263 bp sequence proximal to the start of exon A1, is sufficient to drive expression in breast cancer cells but not in normal, human mammary epithelial cells (HMEC). By combining the disparate technologies of microarray and computerbased transcription factor binding site analyses on this promoter sequence the myc-associated zinc finger protein (MAZ) was identified as a candidate transcription factor mediating tumor-specific expression. Western blot analysis and chromatin immunoprecipitation assays verify that MAZ is overexpressed in MCF-7 cells and is capable of binding to the 263 bp promoter fragment, respectively. Furthermore, the over-expression of MAZ in HMEC is sufficient to drive the expression of PPARc1 and does so by recruiting the tumor-specific promoter. This results in an increase in the amount of PPARc1 capable of binding to its DNA response element. These findings help to define the molecular mechanism driving the high expression of PPARc1 in breast cancer and raise new questions regarding the role of MAZ in cancer progression.
Introduction
Breast cancer is the second leading cause of malignancy related deaths among American women [1] . The majority of these breast tumors arise from the ductile epithelia and infiltrating ductal carcinomas account for over 70% of all cases of breast cancer [2] . Current chemotherapies entail significant toxicity and benefit only a limited number of patients. Due to limitations in current therapeutic options, and the high degree of prevalence, a great deal of research has focused on the search for new and more selective molecular targets in the treatment of breast cancer. A number of nuclear hormone receptors have been identified as potential candidates for use as drug targets including peroxisome proliferator-activated receptor gamma 1 (PPARc1). Our identification of PPARc1 in breast cancer [3] and the subsequent elucidation of its role in mediating differentiation [4, 5] has lead to the intensive examination of its role in mediating similar programs in breast adenocarcinomas [6] [7] [8] .
Peroxisome proliferator-activated receptor gamma 1 is a member of the nuclear hormone receptor superfamily and plays a critical role in adipogenesis [4, 5, 9] , insulin mediated glucose homeostasis [10] , and development [11] .
Ligands for PPARc1 include 15-deoxy-D 12,14 -prostaglandin J 2 (PGJ 2 ), dietary fatty acids and the thiazolidinedione class (TZDs) of hypoglycemic drugs [12] [13] [14] [15] . At the protein level, two forms of PPARc (c1 and c2) are expressed from the same gene, c2 containing an additional 30 N' terminal amino acids not present on c1 [9, 16, 17] . PPARc1 is expressed in normal, human mammary epithelial cells (HMEC) [7] and established breast cancer cell lines where it is functionally responsive to ligand-mediated transactivation [3, 18] ; however, expression of PPARc1 is higher in several different tumor types when compared to noncancerous tissue [19] [20] [21] [22] [23] . In the case of mammary tissue, normal epithelial cells also express much lower level of PPARc1 compared to breast carcinoma cell lines [6, 7, 15, 18, 24, 25] . Furthermore, Mueller et al. demonstrated that PPARc1 expression was higher in metastatic lesions in the lung compared to the primary breast tumor from the same patient indicating that increasing PPARc1 expression correlates with the progression of breast tumors from formation through metastases [26] .
Although PPARc1 is thought to mediate differentiation in most tissues, its role in tumor progression or suppression is poorly understood. Indeed, in some tissues it has been shown that a reduction in the expression of PPARc1 can increase the risk of carcinogenesis. In these studies, PPARc1 heterozygous (+/-) knockout mice had a much greater rate of colon tumor formation following exposure to azoxymethane, an inducer of colorectal cancer [27] . These animals also develop more mammary tumors following exposure to 7,12-dimethylbenz(a)anthracene [28] . By contrast, constitutive over-expression of PPARc1 in animal studies increases the risk of spontaneous breast cancer in mice already susceptible to the disease [29] . It has been suggested that this paradox might be resolved by careful dose-response studies, where both the level of PPARc1 gene expression and transactivation are carefully controlled [30] . This would suggest that the level of expression is a critical factor in determining the physiological outcome of PPARc1 transactivation in a cellspecific context. Since benign breast ducts express lower levels of PPARc1 protein compared to infiltrating carcinoma cells [6] and the expression of PPARc1 is positively correlated with breast cancer metastasis [26] , it is critical that we understand the mechanisms that drive these changes in PPARc1 expression that accompany tumor progression. Therefore, we sought to identify the molecular mechanisms that mediate the increase in PPARc1 as cells progress from normal mammary epithelial to breast carcinoma cells.
We have previously reported that the expression of PPARc1 is under complex regulatory mechanisms [17] . Although we identified distinct promoters associated with untranslated first exons that mediate the changes in expression seen during cellular transformation, we were unable to identify the factor(s) mediating this event. Here we report that through the novel combination of standard promoter analysis, computer-based cis-element prediction and microarray analysis we have identified the myc-associated zinc finger protein (MAZ) as the tumor-specific regulator of PPARc1 in human breast cancer cell lines.
Methods
Cell culture MCF-7 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in DMEM lacking phenol red (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (Hyclone) at 37°C in a 5% CO 2 atmosphere. Cells were grown in T-75 flasks prior to transfer to 12-well plates (Corning) used in transfection assays. Normal, HMEC were obtained from Cambrex/Clonetics. HMEC cells were cultured in the Cambrex/Clonetics MEGM 1 media containing SingleQuot 1 , tissue culture media supplements optimized for the growth of these cells. HMEC were grown in phenol red free medium at 37°C in a 5% CO 2 atmosphere. HEMC were grown in T-75 flasks prior to transfer to 12-well plates used in transfection and assays.
Plasmid construction
The pRL-TK vector (Promega, Madison, WI, USA) was used as an internal control in all transient transfection assays. The PPARc1 3 kb promoter section and the series of 5 0 -end deletion fragments from the 5 0 -flanking region of exon A1 were cloned into the multiple cloning site of the pGL3-basic plasmid (Promega). The MAZ cDNA from human B-cells was obtained from ATCC. Using a combination of Xho I and EcoR I restriction enzymes, the MAZ gene was released from the pOTB7 plasmid and cloned into the pCI/IRES-hgfp mammalian expression vector where the CMV promoter drives MAZ gene expression. PCR was used to introduce the mutated MAZ response element, which substituted one of the guanine triplet sequences to a non-functional TCC sequence. As shown, the native MAZ response element found in the 263 bp sequence of the PPARc pA1 promoter was -217 GGGAGGGA -209, and was changed to the mutant form -217 GGGATCCA -209 while maintaining the context of the 263 bp pA1 promoter in the pGL3-basic luciferase reporter plasmid.
Transient transfection analysis
Cells were transiently transfected with either 2 lg of a 3XPPRE-TK-pGL3 reporter vector [17] , 2 lg of MAZ expression vector, or 0.5 lg pRL-TK (Promega) per plate using ESCORT (Sigma, St Louis, MO, USA). After 18-24 h, cells were lysed in 100 ll passive lysis buffer (Promega) and treated according to manufacturer's instructions for use with the Daul-Luciferase Assay Kit. Luminometry was performed on a Berthold Technologies Lumat (LB9507, Bad Wildbad, Germany) and data calculated as raw luciferase units divided by raw Renilla units (RLU's). Data are presented as the mean fold induction. These values were obtained by dividing the RLU data from each treatment well by the mean of the control values ± the standard error of the mean (sem) as shown.
Sequence analysis for putative cis-elements
Transcription Element Search Software (TESS), a stringbased search tool similar to local alignment software [31] was used to search the 263 bp promoter sequence of PPARc pA1. Using sequence position weight matrices from TRANSFAC, IMD, and the CBIL-GibbsMat databases, possible transcription factor binding sites within the 263 bp region of the PPARc promoter A1 were identified.
Formaldehyde cross-linking and chromatin immunoprecipitation
Cell growth and chromatin preparation were performed according to the manufacturer's instructions included with the ChIP-IT TM kit (Active Motif North America, Carlsbad, CA, USA). Chromatin from MCF-7 cells was formaldehyde cross-linked in a 1.6% solution for 10 min followed by enzymatic shearing for 11 min. Soluble chromatin from MCF-7 cells was immunoprecipitated with a MAZ polyclonal antibody (Santa Cruz Biotechnology, sc-28745, Santa Cruz, CA, USA). Specific primer pairs (Integrated DNA Technologies, Coralville, IA, USA) were designed to amplify the PPAR gamma promoter regions from -210 to -1, forward primer: 5 0 GCCGCTCCCTCCCAGTCGTCGCG 3 0 ; reverse primer: 5 0 CTCGAGGCCGACCCAAGC 3 0 . PCR fragments were analyzed by 5% polyacrylamide gel (37.5:1, acrylamidebisacrylamide) in TBE buffer. The 210 bp fragment was purified and subjected to DNA sequence analysis. Elim Biopharmaceuticals, Inc. (Hayward, CA, USA) performed all DNA sequencing.
Nuclear protein extraction
Nuclear proteins were prepared with the nuclear extract kit (Active Motif North America). In brief, cells were scraped into PBS containing phosphatase and protease inhibitors, centrifuged, resuspended in a 1· hypotonic buffer and then kept on ice for 15 min. After the addition of a detergent, the lysates were centrifuged at 14,000·g for 30 s at 4°C. The pellets were resuspended in complete lysis buffer and vortexed for 10 s at the highest setting. After a 30-min incubation on ice and centrifugation at 14,000·g for 10 min at 4°C, the supernatants were collected, and the protein concentration was determined with a BCA protein assay kit (Pierce, Rockford, IL, USA).
PPAR gamma transactivation analysis
Peroxisome proliferator-activated receptor gamma 1 activation was determined with the TransAM ELISA kit (Active Motif North America). Nuclear extract was added to each well of a 96-well plate into which an oligonucleotide with a PPAR consensus binding site had been immobilized. After 1 h of incubation with smooth agitation, wells were washed three times with washing buffer and then incubated with PPARc1 antibody (1:250 dilution in 1· antibody binding buffer) for 1 h at room temperature. The wells were washed three times and incubated for 1 h with diluted anti-rabbit HRP-conjugated antibody (1:1,000 dilution in 1· antibody binding buffer). After four wash cycles, 100 ll of developing buffer was added to each well and incubated for 5-8 min. The reaction was stopped by the addition of 100 ll stop buffer. The final A 450 was read on a Kinetic microplate reader with a reference wavelength of 650 nm.
Western blot analysis
Western analysis was performed as described previously [17] using the nuclear fractions from MCF-7 and HMEC. The Anti-MAZ polyclonal antibody was purchased from Santa Cruz (1:200 dilution, sc-28745; Santa Cruz Biotechnology). To assess sample loading, a-Tubulin (1:1,000 dilution, sc-8035, Santa Cruz Biotechnology) was used as a loading control. An estimation of the relative quantity of MAZ was determined by densiometry using a Kodak Imaging System EL Logic 2200. The observed MAZ protein level was recorded as a ratio of MAZ to tubulin.
Affymetrix microarray analysis
Total RNA was isolated from cells following a 3-h treatment using the Qiagen RNeasy Mini Kit. The University of Kentucky Microarray Core Facility verified the total yield by both gel electrophoresis and Agilient Bioanalyzer. The core facility processed the total RNA samples to produce biotinylated, fragmented cRNA. The cRNA samples then were hybridized to the Affymetrix (Santa Clara, CA, USA) HG-U133A GeneChip and washed with a streptavidin phycoerythrin solution via an Affymetrix Fluidics Station 400. Finally, the resultant florescent intensities were collected and analyzed using an Affymetrix GeneArray Scanner coupled to a computer workstation running Affymetrix Microarray Suite (MAS 5.0). The MAS 5.0 data from each Gene Chip was saved and exported into Microsoft Excel spreadsheets (Redmond, WA, USA). MAS 5.0 signal intensity data collected were aggregated into a single Excel spreadsheet using the probe set IDs, signal intensity values, and signal detection flag for each sample and probe set description. Mean signal intensity values (n = 3 per cell type) were reported along with SE as an appropriate estimation of error. One factor analysis of variance (ANOVA, a = 0.05) followed by t-test was used to determine significant differences in the observed treatment effect within a cell type.
Quantitative real-time PCR
A one-step quantitative real-time PCR technique was used to determine relative expression levels of PPARc1 mRNA using the ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The RNeasy Mini Kit (Qiagen) was used to isolate the total RNA. The pre-optimized primers and probe with FAM reporter fluorescent dye for PPARc were purchased from Applied Biosystems, assay-on-demand number Hs00234592_m1. For the internal control, 18S, a pre-optimized primer and probe also was used, assay-on-demand number Hs99999901_s1. A one-step reaction reagent mixture provided in the TaqMan One-step RT-PCR Master Mix kit (Applied Biosystems) was used for all of the amplifications. Cycle parameters for the one-step reverse transcription-PCR included a reverse transcription step at 48°C for 30 min, followed by 40 cycles of 95°C denaturation and 60°C annealing/extension. The house keeping gene 18S was used for internal normalization.
Analysis methods as outlined in the ABI Prism 7700 Sequence Detection System User Bulletin 2 (October 2001) were performed using the relative C t method. Briefly, this method uses the mathematical expression 2 ÀC t to estimate the relative gene expression based on a calibrated sample, DC t = C t,x -C t,calibrator , and the gene target of interest normalized to the expression of an endogenous housekeeping gene like 18S, DDC t = C t,PPAR -C t,18S . The mean (n = 4 per cell line) values were reported along with the SE of the C t because an appropriate estimation of error was calculated from the SDs of the C t values for PPAR and 18S through the formula SE = s/n where the SD,
Results
Identifying transcription factors mediating tumorspecific expression of PPARc1
We have previously reported that the regulation of PPARc1 expression is under the control of at least six different promoters associated with distinct, first exons [17] . We have also demonstrated that the higher levels of PPARc1 expression reported in breast cancer cells results from the recruitment of a distinct tumor-specific promoter termed pA1, which is not used in HMECs [17] . To define the factor driving expression from pA1, we initially used 5 0 -end deletion analysis of the 3,000 bp pA1 promoter fragment. These analyses allowed us to more narrowly define the promoter element(s) using luciferase reporters. In addition to the 3 kb pA1 promoter fragment, a 2-kb fragment from -1 to -2000, a 1-kb fragment from -1 to -1000, a 263-bp fragment from -1 to -263 and a 5 0 end 2 kb fragment from -1000 to -3000 were generated (Fig. 1a) . These data indicate that the proximal 263 bp of the pA1 promoter fragment contain the element(s) necessary to drive expression of PPARc1 in breast cancer cells.
The 263 bp pA1 promoter fragment is greater than 90% GC-rich and resisted efforts to more narrowly define the response element by standard deletional analysis (data not shown). To circumvent these limitations and define the element(s) within the 263 bp fragment driving expression, we integrated two distinct technological approaches to identify potential transcription factor binding sites. Using the Transcription Element Search System (TESS, (http://www.cbil.upenn.edu/tess/), developed at the University of Pennsylvania Computational Biology and Informatics Laboratory, we identified the potential transcription factor binding sites within this 263 bp tumorspecific promoter fragment [32] . This approach identified 29 different transcription factors that had the potential to bind at a total of 209 different DNA binding sites. We then used microarray analysis to determine which of the factors identified by TESS analysis were expressed at significantly higher levels in breast cancer cells relative to HMECs. These analyses revealed that of the transcription factors on the HG-U133A array, MAZ was significantly over expressed in estrogen-dependent breast cancer (MCF-7) cells compared to HMEC (Fig. 1b) . This message was represented by two different probes sets, and both were significantly higher in the MCF-7 cells relative to HMEC. Densiometric analysis of the western blot confirms that is expressed at significantly higher levels in the nuclear extracts of MCF-7 cells (Fig. 2a, arrow marked bands) .
To resolve whether the binding site identified by TESS analysis is recognized and bound by MAZ, Chromatin immunoprecipitation (ChIP) assay was preformed. Using the polyclonal antibody to MAZ and the gene-specific primers, the expected band size of 210 bp was amplified (Fig. 2b ). This fragment was purified and sequenced confirming this to be the pA1 promoter. Electrophoretic mobility shift assays (data not shown) confirmed the ChIP assay that MAZ binds to the MAZ response element (MAZ-RE) identified by TESS. Together these demonstrate that MAZ is overexpressed in tumors and physically binds to the endogeneous response element within the -263 bp pA1 promoter in MCF-7.
The expression of MAZ drives PPARc1 expression in MCF-7 cells
Initially, we examined the ability of MAZ to mediate reporter activity of the 263 bp promoter shown to control tumor-specific expression of PPARc1. In MCF-7 cells, this promoter is sufficient to confer transcriptional regulation compared to the basic (pGL3-basic) luciferase reporter (Fig. 3a) . Furthermore, when a MAZ expression plasmid is introduced into these cells reporter activity is significantly higher than MCF-7 cells not overexpressing MAZ (Fig. 3  a) . To confirm the need of the MAZ response element, this element was scrambled by site directed mutagenesis where the second G triplet sequence was replaced with TCC. When this mutated MAZ-RE was placed within the context of the 263 bp promoter, reporter activity was significantly reduced (Fig. 3b) .
Expression of MAZ in HMEC cells drive PPARc expression from the tumor-specific promoter
Transient transfection of HEMC with the MAZ expression vector dramatically increased mRNA levels of PPARc1 as seen by real-time PCR (Fig. 4a) . This also resulted in a small but significant increase in protein levels (Fig. 2a , band marked by arrow). Since breast cancer cells drive expression of PPARc1 from a tumor-specific promoter not used by HMEC, probes were designed to determine whether MAZ drives PPARc1 expression from the tumorspecific promoter in HMECs as well. Exon-specific probes to the first exon (A1) present on PPARc mRNA from MCF-7 cells and the first exon present on PPARc1 from HMEC (A3) [17] were used to amplify the mRNA from HMEC expressing MAZ. These data demonstrate that MAZ drives expression of PPARc1 in HMEC (Fig. 4a, insert) from pA1, the tumor-specific promoter [17] . Finally, to determine whether the MAZ-driven increase in PPARc1 increases the amount of protein capable of binding DNA, an ELISA-based assay to quantitate the binding of PPARc to its response element was used. These data demonstrate that MAZ expression increases not only the level of PPARc1 protein in HMEC but also the amount of PPARc1 capable of binding to DNA.
Discussion
A rapidly growing body of work has demonstrated that the transactivation of PPARc1 by various exogenous ligands mediates a wide range of responses including growth arrest, differentiation and apoptosis making this nuclear receptor a possible target for cancer therapy [7, 8] . We have shown that PPARc1 is highly over expressed in many tumors including breast, colon and lung [18] . In order to examine the transcriptional regulation of PPARc1, we have determined its genomic structure and shown that the rise in expression from normal, human mammary epithelia to breast cancer is due to the recruitment of a distal, tumorspecific promoter element, termed pA1 [17] . The studies outlined in this report were designed to identify the mechanism driving this increase in PPARc1 expression. Through standard 5 0 -end deletion analysis, we sought to determine the transcription factor that mediates the recruitment of the pA1 promoter. Although we were able to narrow the response element to a 263-bp fragment immediately flanking the start site of transcription, the GC-rich nature of this region made further promoter analysis by standard methods intractable. Therefore, we chose to take a novel approach that combined two disparate technologies to identify the factor mediating the tumor-specific expression of PPARc1 in breast cancer. In addition to having identified a novel transcription factor whose expression could have an important role in cancer biology, this approach could find broader use in locating response elements and identifying the transcription factors that drive the expression of genes of interest.
By using the transcription element search system developed at the University of Pennsylvania, we were able to locate potential transcription factor binding sites within the proximal 263 bp PPARc1 promoter fragment. Since PPARc1 is highly expressed in MCF-7 cells relative to HMEC, we sought to determine which of the transcription factors identified by TESS were also over expressed in MCF-7 cells. For this, we employed data from a microarray analysis currently underway in the lab. We examined the expression levels of all the transcription factors identified by TESS that were present on the HG-U133A chip for factors overexpressed in MCF-7 cells compared to HMEC. Microarray analysis indicated that MAZ is expressed at significantly higher levels in MCF-7 cells. Indeed, MAZ is represented by two different probe sets on the HG-U133A chip and both were significantly higher in MCF-7 cells. Western blot analysis confirms that this is true at the protein level as well. Furthermore, ChIP assay proved that in vivo MAZ binds to the MAZ response elements in the 263 bp pA1 promoter fragment. The forced overexpression of MAZ in HMEC also drives an increase in the expression of PPARc1. Furthermore, not only does MAZ drive (Fig. 2 a) confirmed the expression of MAZ. PPARc1 mRNA is dramatically increased in the presence of MAZ expression. PCR, using pA1 specific primers, verify that only in the presence of MAZ is the exon associated with the tumor-specific promoter used (insert). For real-time PCR, the data shown represent two independent experiments with three technical replicates for each treatment. (B) The ability of MAZ expression to increase the amount of PPARc able to bind to a PPRE was measures by ELISA using DNA as the immobilized target. Following the expression of MAZ the amount of PPARc bound to its response element is significantly increased. For transactivation analysis, the data shown represent three independent experiments each with three biological replicates for a total of nine observations per treatment expression of PPARc1 in HMEC, it does so from the tumor-specific promoter. Finally, mutating the MAZ-RE in the context of the tumor-specific promoter inhibits reporter activity and provides further support of its role in mediating the expression of PPARc1 in breast cancer. These data have led us to hypothesize that MAZ plays a critical role in tumorgenesis and this is currently being tested in the lab. The prevalence of MAZ expression in breast cancer is unknown and is also currently under investigation in the lab.
Through development, differentiation and tumorgenesis, genes can be silenced and activated by several mechanisms. Clearly acetylation and deactivation of histones in the region of targeted genes has been shown to regulate expression, as has the methylation of CpG islands. Changes in the expression of transcription factors during these events can also play a critical role. These data demonstrate that the upregulation of MAZ is responsible, at least in part, for driving the increase in PPARc1 expression and may also play a role in tumor progression. Although the tumorspecific prompter is very GC-rich, and therefore a potential target for methylation, this does not appear to be preventing use of this element. This is evident by the fact that when normal epithelial cells are forced to express MAZ, not only does this increase the expression of PPARc1, but it does so using the tumor specific, GC-rich, promoter to drive expression. Although MAZ clearly drives an increase in the expression of PPARc1 during tumor formation, it is not known what other genes are regulated by MAZ and what is the underlying mechanism that regulates MAZ expression. Therefore, it will be critical to understand the range of genes under the direct and indirect control of MAZ and define the consequences of MAZ expression to the mammary epithelia function. These questions are critical to our understanding of the consequences of regulation of both PPARc1 and MAZ and are currently under investigation in the laboratory. These studies also highlight the usefulness of integrating the disparate technologies of computer based genomic analysis with expression patterns gleaned from microarray analysis to identify transcription factors involved in gene regulation. This is especially true of complex promoters such as that described here. This approach might also be useful in identifying the combination of factors that coordinate the expression of target genes including those that directly bind DNA as well as coactivators and co-repressors that coordinate the actions of the transcriptisome.
Experiments preformed in vitro clearly demonstrate the potential of targeting PPARc1 in the treatment of breast cancer [26, 28] . In addition, animal studies support the role for using PPARc1 ligands for both the treatment and prevention of breast cancer [28] , and clinical data is now emerging supporting the in vitro and animal studies that demonstrate a protective role of PPARc1 ligands in the treatment and prevention of breast cancer in women (http://www.proactive-results.com). In these studies, a significant reduction in the occurrence of breast cancer was seen in type 2 diabetic patients taking the thiazolidinedione Pioglitazone. It is critical, however, that we understand what role the level of PPARc1 expression plays in mediating the responses of these ligands on growth suppression and apoptosis. The work outlined in these studies provide a much needed basis for assessing these changes and determining whether the expression of other factors will alter a patients response to drugs targeting PPARc1.
